Rapacan 1mg (Sirolimus)

Sirolimus
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Biocon Ltd.

Rapacan 1mg (Sirolimus)

ManufacturerBiocon Ltd.Brand nameRapacanActive substanceSirolimusStrength1mgCategoryNephrologyManufacturerBiocon Ltd

Description of Rapacan 1mg (Sirolimus 1mg)

Rapacan 1mg (Sirolimus 1mg) belongs to immunosuppressant agent required to prevent organ refusal in renal transplants, in concomitant use with corticosteroids and cyclosporine.
It is also needed to inhibit rejection in heart transplant and for immunosuppression for stem cell/bone marrow transplants.

Rapacan 1mg (Sirolimus 1mg) which is prescribed as prescription medicine under supervision of medical practioners.

Medical use /Indication of Rapacan 1mg (Sirolimus 1mg)

Indicated for the prophylaxis of organ refusal in patients aged 13 years or older diagnosed renal transplants.

Mechanism of Action Rapacan 1mg (Sirolimus 1mg)

Sirolimus blocks the T-lymphocytes activation and multiplicationwhich occurs in response to antigenic and cytokinin (Interleukin [IL]-2, IL-4, and IL-15) activated by a mechanism which is distinct from that of other
immunosuppressants. Sirolimus also prevents antibody production. In cells, sirolimus joints to the immunophilin, FK Binding Protein-12 (FKBP-12), to produce an immunosuppressive complex. Sirolimus consist of FKBP-12 complex has no effect on calcineurin activity. This complex link to and prevents the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This prevention suppresses cytokine-driven T-cell replication, preventing the progression from the G1 to the S phase of the cell cycle.

ADME of Rapacan 1mg (Sirolimus 1mg)

The high plasma concentration is 1-2 hours in healthy patients and renal transplant patients and bioavailability are 27%.

The medicine hasserum protein binding is 92%

Rapacan 1mg (Sirolimus 1mg) is widely metabolized in the intestinal wall and liver. It is substrate for both CYP3A4 and P-gp

Most of radioactivity was recovered from the faces is 91% and only little amount was excreted in urine is 2.2%.

Half-life of Rapacan 1mg (Sirolimus 1mg) is 57-63 hours.

Side effects of Rapacan 1mg (Sirolimus 1mg)

Common side effects :

  • Fever, cold and cough
  • Mouth sores;
  • Nausea, stomach pain, diarrhoea;
  • Headache, muscle aches;
  • Chest pain;
  • Dizziness; or
  • Acne.

Other side effects, if it occurs then immediately call doctor :

  • Slow healing of a skin wound;
  • A new skin lesion,
  • Unusual bleeding
  • Sudden discomfort in chest, cough, feeling short of breath;
  • Pain around the transplanted kidney;
  • Infection like--fever, chills, painful mouth sores, skin sores, cold or flu symptoms, pain or burning when you urinate; or
  • Anemia- skin in pale, unusual weakness, feeling light-headed or Dyspnea cold hands and feet.

Precautions of Rapacan 1mg (Sirolimus 1mg)

Rapacan 1mg (Sirolimus 1mg) should be prescribed only by physicians who have experience with immuno suppression in organ transplant recipients and can supply necessary follow-up and appropriate checking

Usage in liver or lung transplantation as safety and efficacy is not established.

In liver transplant recipients have been noticed having high mortality, loss in graft, and hepatic artery thrombosis

In lung transplant recipients has been noticed Bronchial anastomotic dehiscence

Rapacan 1mg (Sirolimus 1mg) will have high risk of infection, lymphoma, and other malignancies due to raise immunosuppression

Greatest enhance sun exposure due to increased skin cancer risk

Patients generally presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia will have resulted Progressive multifocal leukoencephalopathy (PML), sometimes fatal

Drug interaction of Rapacan 1mg (Sirolimus 1mg)

Rapacan 1mg (Sirolimus 1mg) co administration with cyclosporine will increases sirolimus concentration. Hence sirolimus should give 4 hours after administration of cyclosporine

Avoid co administration of Rapacan 1mg (Sirolimus 1mg) with strong inducers and strong inhibitors will decrease interaction potential with sirolimus

Using with grapefruit juice will blocks the CY3A4 – mediated metabolism of Rapacan 1mg (Sirolimus 1mg). Avoid during using with sirolimus

Contraindication of Rapacan 1mg (Sirolimus 1mg)

hypersensitivity to sirolimus

Pregnancy of Rapacan 1mg (Sirolimus 1mg)

Pregnancy category is C

Rapacan 1mg (Sirolimus 1mg): There are no adequate and well-indulge studies in pregnant women. Active contraception should beinitiate before sirolimus therapy, during sirolimus therapy, and Emtor treatment has been stopped after 12 weeks.

Lactation of Rapacan 1mg (Sirolimus 1mg)

Many medicines are excreted in human milk, and because of the probable unacceptable effects in nursing infants from Rapacan 1mg (Sirolimus 1mg), a decision should be considered whether to halt for nursing or to stop the medicine, considering the requirement of the medicine to the mother.

Dosage of Rapacan 1mg (Sirolimus 1mg)

RAPACAN 1MG (SIROLIMUS 1MG) IS USED FOR THE PROPHYLAXIS OF RENAL TRANSPLANT REJECTION :

Initiating treatment concomitant use with cyclosporine and corticosteroids :

High immunologic risk

The usual loading dose is <40 kg: 3 mg/m² ≥40 kg: 15 mg PO loading dose Sustenance dose of Rapacan 1mg (Sirolimus 1mg) is 5 mg/day PO if >40 kg and 1 mg/m²/day if <40 kg on day 2 and after that; produce trough levels between days 5 and 7.

Dose should be adapting to control trough concentrations within desired range based on clinical state and concomitant therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment

Combination therapy: For the first year, continuing transplantation, Rapacan 1mg (Sirolimus 1mg) should be used in interaction with cyclosporine and corticosteroids; cyclosporine may be initiated at 7 mg/kg/day in double doses with the dose modify to get trough concentrations; prednisone should be taken at a dose of 5 mg/day

Low-to-moderate immunologic risk

The usual loading dose <40 kg: 3 mg/m² ≥40 kg: 6 mg PO loading dose Sustenance: 2 mg/day PO if ≥ 40 k g and 1 mg/m²/day if <40 kg on day 2 and thereafter; obtain trough levels between days 5 and 7

Dose should be adapting to control trough concentrations within desired range based on clinical state and concomitant therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment

Combination therapy: continuing transplantation, Rapacan 1mg (Sirolimus 1mg) should be used in interaction with cyclosporine and corticosteroids; may stops cyclosporine gradually over 4-8 weeks two to four months after transplant in patients with low immunologic risk, & Rapacan 1mg (Sirolimus 1mg) dose higher (serum concentrations of sirolimus may reduce following cyclosporine withdrawal)

LYMPHANGIOLEIOMYOMATOSIS :

Rapacan 1mg (Sirolimus 1mg) prescribed for therapy of lymphangioleiomyomatosis (LAM)

Initial prescribeddose: 2 mg/day PO given in 10-20 days and then monitor whole blood trough level

Over dosage :

If overdose occurs all should provide general supportive measures.

Storage of Rapacan 1mg (Sirolimus 1mg)

Rapacan 1mg (Sirolimus 1mg) Stored at 20℃-25℃ Avoid using if blister is torn or broken.

Missed dose of Rapacan 1mg (Sirolimus 1mg)

If dose is missed to take, have immediately before next dose reaches or skip the dose and follow normal timing.
Please Consult with the doctor.

Brand name:
Rapacan
Active substance:
Sirolimus
Strength:
1mg
Category:
Nephrology
Manufacturer:
Biocon Ltd
Packaging:
10 tablets
Product form:
Tablet

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India